A “PRECISION MEDICINE” STRATEGY FOR RECURRENT GLIOBLASTOMA

por Prados, Michael
Publicado em 2014

“We will know it when we see it;” bevacizumab and glioblastoma

por Prados, Michael D.
Publicado em 2014

Plexiform neurofibromas, trial design, and the definitions of “progression” and “treatment failure”

por Prados, Michael D.
Publicado em 2014

Recurrent asymptomatic demyelinating disease following 13-cis-retinoic acid exposure

por Okuda, Darin T, Prados, Michael D
Publicado em 2009

Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis

por Lamborn, Kathleen R., Chang, Susan M., Prados, Michael D.
Publicado em 2004

Letters To The Editor

por Meyers, Christina A., Lamborn, Kathleen R., Prados, Michael D.
Publicado em 2008

Clinical trial endpoints for patients with gliomas

por Taylor, Jennie W, Molinaro, Annette M, Butowski, Nicholas, Prados, Michael
Publicado no Neurooncol Pract (2017)

Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity

por Han, Seunggu J., Yang, Isaac, Tihan, Tarik, Prados, Michael D., Parsa, Andrew T.
Publicado em 2009

High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system

por Nicolaides, Theodore, Tihan, Tarik, Horn, Biljana, Biegel, Jaclyn, Prados, Michael, Banerjee, Anuradha
Publicado em 2009

Reply to J.W. Locasale et al

por de Groot, John F., Heimberger, Amy, Prados, Michael D., Wen, Patrick Y.
Publicado em 2012

Surgery, a prognostic marker for progression-free survival?: Reply

por Clarke, Jennifer L., Ennis, Michele M., Prados, Michael D., Lamborn, Kathleen R.
Publicado em 2012

NI-61 VOLUMETRIC H-1 MR METABOLIC IMAGING FOR DEFINITION OF LESION BURDEN AND PREDICTION OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED GBM

por Nelson, Sarah, Li, Yan, Prados, Michael, Butowski, Nicholas, Clarke, Jennifer, Chang, Susan
Publicado em 2014

RB1 SUPPRESSION IS RESPONSIBLE FOR ACQUIRED CDK4/6 INHIBITOR RESISTANCE IN GLIOBLASTOMA

por James, C. David, Lu, Yu-Jen, Ozawa, Tomoko, Prados, Michael D., Waldman, Todd
Publicado em 2014

SG-01 FEEDBACK ACTIVATION OF EGFR VIA PTPN9 LEADS TO GLIOMA ESCAPE FROM BRAF(V600E) TARGETED THERAPY

por Yao, Tsun-Wen, Zhang, Jie, Prados, Michael, Weiss, William, James, David, Nicolaides, Theodore
Publicado no Neuro Oncol (2015)

An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing

por Aoki, Yasuyuki, Hashizume, Rintaro, Ozawa, Tomoko, Banerjee, Anu, Prados, Michael, James, C. David, Gupta, Nalin
Publicado em 2012

EGFR blockade prevents glioma escape from BRAF(V600E) targeted therapy

por Yao, Tsun-Wen, Zhang, Jie, Prados, Michael, Weiss, William A., James, C. David, Nicolaides, Theodore
Publicado no Oncotarget (2015)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas

por Yao, Tsun-Wen, Zhang, Jie, Prados, Michael, Weiss, William A., James, C. David, Nicolaides, Theodore
Publicado no Oncotarget (2016)

AT-25 A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA

por Han, Seunggu, Martin, Alastair, Berger, Mitchel, Prados, Michael, Chang, Susan, Clarke, Jennifer, Bankiewicz, Krystof, Butowski, Nicholas
Publicado em 2014

GENE-20. MULTI-GENE MUTATION PROFILING OF PEDIATRIC MIDLINE GLIOMAS USING PATIENT LIQUID BIOPSY

por Bonner, Erin, Panditharatna, Eshini, Kambhampati, Madhuri, Virata, Michael, Singh, Priyam, Prados, Michael, Mueller, Sabine, Nazarian, Javad
Publicado no Neuro Oncol (2019)

Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma

por Cooney, Tabitha, Yeo, Kee Kiat, Kline, Cassie, Prados, Michael, Haas-Kogan, Daphne, Chi, Susan, Mueller, Sabine
Publicado no Neurooncol Pract (2020)